Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis | MicrobiomeTrials← Back to trialsNCT07520110
Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2026-09-28Est. Completion: 2029-03-15
Enrollment target: 800 participants Locations- University of Arizona, Tucson, Arizona, United States
- University of Colorado Anschutz, Aurora, Colorado, United States
- Georgetown University Hospital, Washington D.C., District of Columbia, United States
- Northwestern University, Chicago, Illinois, United States
- University of Chicago, Chicago, Illinois, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Weill Cornell Medicine, New York, New York, United States
- Temple University, Philadelphia, Pennsylvania, United States
- University of Texas Southwestern, Dallas, Texas, United States
- Michael E. DeBakey VA Medical Center, Houston, Texas, United States
- University of Utah, Salt Lake City, Utah, United States
- University of Washington, Seattle, Washington, United States
Other microbiome trials you might be interested in
Interstitial Lung DiseaseChronic Obstructive Pulmonary DiseaseHypoxemia
Fibrotic forms of interstitial lung disease (ILD) and chronic obstructive pulmonary disease (COPD) are chronic lung dise…
Buffalo, United StatesCompleted Oct 2027
Idiopathic Pulmonary Fibrosis (IPF)
Rationale: LTI-03 is an experimental medication breathed into the lungs using an inhaler. It is being studied for the tr…
Birmingham, United StatesEst. completion Sep 30, 2027